Century Therapeutics reports Q1 net loss of $21.6M; cash runway into Q1 2029; CNTY-813 IND on track for 4Q 2026

Century Therapeutics, Inc.

2026-Q1 EPS reported -$0.11

Net loss of $21.6M for Q1 2026 vs net income of $76.6M in Q1 2025; R&D $17.1M, G&A $6.6M.
Cash, cash equivalents and marketable securities $217.0M as of March 31, 2026; runway into Q1 2029.
CNTY-813 (type 1 diabetes iPSC islet) IND submission on track for 4Q 2026; initial clinical data expected 2H 2027; ADA presentation June 8, 2026.
CNTY-308 (CD19 CAR-iT) to enter clinic in 2026 pending regulatory clearance; targeting B-cell mediated diseases.
Completed $135M oversubscribed private placement in January 2026; net cash used in ops $25.3M (down from $34.6M).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Century Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net (loss) was $21.6 million for the quarter ended March 31, 2026, compared to net income of $76.6 million for the same.

Period: the first quarter ended March 31, 2026
Net income: Net (loss) was $21.6 million for the quarter ended March 31, 2026, compared to net income of $76.6 million for the same
Result: reported results

Exact text from the filing

Century Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2026.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Century Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-059824

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.